Pathophysiology of typical hemolytic uremic syndrome

Seminars in Thrombosis and Hemostasis

Volumn 36, Issue 6, 2010, Pages 575-585

  Karpman, Diana ^a   Sartz, Lisa ^a   Johnson, Sally ^b  

^a LUND UNIVERSITY   (Sweden)

^b BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

enterohemorrhagic Escherichia coli; Hemolytic uremic syndrome; kidney; Shiga toxin; thrombotic microangiopathy

Indexed keywords

COMPLEMENT; CYTOLETHAL DISTENDING TOXIN; CYTOTOXIN; HEMOLYSIN; SHIGA TOXIN; VIRULENCE FACTOR;

BACTERIAL COLONIZATION; BLOOD FLOW; BRAIN; BRAIN DAMAGE; CIRCULATION; DISEASE COURSE; ENTEROHEMORRHAGIC ESCHERICHIA COLI; GASTROINTESTINAL INFECTION; HEMOLYTIC UREMIC SYNDROME; HISTOLOGY; HOST PATHOGEN INTERACTION; HUMAN; INTESTINE; KIDNEY; KIDNEY INJURY; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TARGET ORGAN;

ENTEROHEMORRHAGIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI O157; HEMOLYTIC-UREMIC SYNDROME; HOST-PATHOGEN INTERACTIONS; HUMANS; INTESTINAL MUCOSA; VIRULENCE; VIRULENCE FACTORS;

EID: 77957588040     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0030-1262879     Document Type: Review

References (141)

1. Lynn R M., O'Brien S J., Taylor C M. et al. Childhood hemolytic uremic syndrome, United Kingdom and Ireland. Emerg Infect Dis 2005 11 (4) 590-596
2. Loirat C, Marczak E. Haemolytic uraemic syndrome In: Cochat P European Society for Paediatric Nephrology Handbook. Lyon, France Medcom 2002 337-342
3. López E L., Contrini M M., Devoto S et al. Incomplete hemolytic-uremic syndrome in Argentinean children with bloody diarrhea. J Pediatr 1995 127 (3) 364-367
4. Borczyk A A., Karmali M A., Lior H, Duncan L MC. Bovine reservoir for verotoxin-producing Escherichia coli O157:H7. Lancet 1987 1 (8524) 98
5. Karmali M A. Host and pathogen determinants of verocytotoxin-producing Escherichia coli -associated hemolytic uremic syndrome. Kidney Int Suppl 2009 112 (112) S4-S7
6. Goode B, O'Reilly C, Dunn J et al. Outbreak of Escherichia coli O157: H7 infections after Petting Zoo visits, North Carolina State Fair, October-November 2004. Arch Pediatr Adolesc Med 2009 163 (1) 42-48
7. Milford D V., Taylor C M., Guttridge B, Hall S M., Rowe B, Kleanthous H. Haemolytic uraemic syndromes in the British Isles 1985-8: association with verocytotoxin producing Escherichia coli. Part 1: Clinical and epidemiological aspects. Arch Dis Child 1990 65 (7) 716-721 (Pubitemid 20220428)
8. Johnson S, Taylor C M. What's new in haemolytic uraemic syndrome? Eur J Pediatr 2008 167 (9) 965-971
9. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001 60 (3) 831-846 (Pubitemid 34205784)
10. Gagnadoux M F., Habib R, Gubler M C., Bacri J L., Broyer M. Long-term (15-25 years) outcome of childhood hemolytic-uremic syndrome. Clin Nephrol 1996 46 (1) 39-41
11. Dean P, Kenny B. The effector repertoire of enteropathogenic E. coli: ganging up on the host cell. Curr Opin Microbiol 2009 12 (1) 101-109
12. Delahay R M., Frankel G, Knutton S. Intimate interactions of enteropathogenic Escherichia coli at the host cell surface. Curr Opin Infect Dis 2001 14 (5) 559-565
13. Fürst S, Scheef J, Bielaszewska M, Rüssmann H, Schmidt H, Karch H. Identification and characterisation of Escherichia coli strains of O157 and non-O157 serogroups containing three distinct Shiga toxin genes. J Med Microbiol 2000 49 (4) 383-386
14. Boerlin P, McEwen S A., Boerlin-Petzold F, Wilson J B., Johnson R P., Gyles C L. Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans. J Clin Microbiol 1999 37 (3) 497-503
15. Shimizu T, Ohta Y, Noda M. Shiga toxin 2 is specifically released from bacterial cells by two different mechanisms. Infect Immun 2009 77 (7) 2813-2823
16. Zhang X, McDaniel A D., Wolf L E., Keusch G T., Waldor M K., Acheson D W. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infect Dis 2000 181 (2) 664-670
17. Zoja C, Corna D, Farina C et al. Verotoxin glycolipid receptors determine the localization of microangiopathic process in rabbits given verotoxin-1. J Lab Clin Med 1992 120 (2) 229-238
18. Obrig T G., Moran T P., Brown J E. The mode of action of Shiga toxin on peptide elongation of eukaryotic protein synthesis. Biochem J 1987 244 (2) 287-294
19. Zoja C, Angioletti S, Donadelli R et al. Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1. Kidney Int 2002 62 (3) 846-856
20. Matussek A, Lauber J, Bergau A et al. Molecular and functional analysis of Shiga toxin-induced response patterns in human vascular endothelial cells. Blood 2003 102 (4) 1323-1332
21. Petruzziello T N., Mawji I A., Khan M, Marsden P A. Verotoxin biology: molecular events in vascular endothelial injury. Kidney Int Suppl 2009 75 S17-S19
22. Zoja C, Angioletti S, Donadelli R et al. Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1. Kidney Int 2002 62 (3) 846-856
23. Obrig T G., Louise C B., Lingwood C A., Boyd B, Barley-Maloney L, Daniel T O. Endothelial heterogeneity in Shiga toxin receptors and responses. J Biol Chem 1993 268 (21) 15484-15488
24. Friedrich A W., Zhang W, Bielaszewska M et al. Prevalence, virulence profiles, and clinical significance of Shiga toxin-negative variants of enterohemorrhagic Escherichia coli O157 infection in humans. Clin Infect Dis 2007 45 (1) 39-45
25. Bielaszewska M, Karch H. Consequences of enterohaemorrhagic Escherichia coli infection for the vascular endothelium. Thromb Haemost 2005 94 (2) 312-318
26. Friedrich A W., Lu S, Bielaszewska M et al. Cytolethal distending toxin in Escherichia coli O157:H7: spectrum of conservation, structure, and endothelial toxicity. J Clin Microbiol 2006 44 (5) 1844-1846
27. Bielaszewska M, Sinha B, Kuczius T, Karch H. Cytolethal distending toxin from Shiga toxin-producing Escherichia coli O157 causes irreversible G2/M arrest, inhibition of proliferation, and death of human endothelial cells. Infect Immun 2005 73 (1) 552-562
28. Aldick T, Bielaszewska M, Zhang W et al. Hemolysin from Shiga toxin-negative Escherichia coli O26 strains injures microvascular endothelium. Microbes Infect 2007 9 (3) 282-290
29. Paton A W., Srimanote P, Talbot U M., Wang H, Paton J C. A new family of potent AB(5) cytotoxins produced by Shiga toxigenic Escherichia coli. J Exp Med 2004 200 (1) 35-46
30. Paton A W., Beddoe T, Thorpe C M. et al. AB5 subtilase cytotoxin inactivates the endoplasmic reticulum chaperone BiP. Nature 2006 443 (7111) 548-552
31. Hu C C., Dougan S K., Winter S V., Paton A W., Paton J C., Ploegh H L. Subtilase cytotoxin cleaves newly synthesized BiP and blocks antibody secretion in B lymphocytes. J Exp Med 2009 206 (11) 2429-2440
32. McKee M L., O'Brien A D. Investigation of enterohemorrhagic Escherichia coli O157:H7 adherence characteristics and invasion potential reveals a new attachment pattern shared by intestinal E. coli. Infect Immun 1995 63 (5) 2070-2074
33. Kaper J B., Nataro J P., Mobley H L. Pathogenic Escherichia coli. Nat Rev Microbiol 2004 2 (2) 123-140
34. Malyukova I, Murray K F., Zhu C et al. Macropinocytosis in Shiga toxin 1 uptake by human intestinal epithelial cells and transcellular transcytosis. Am J Physiol Gastrointest Liver Physiol 2009 296 (1) G78-G92
35. Phillips A D., Navabpour S, Hicks S, Dougan G, Wallis T, Frankel G. Enterohaemorrhagic Escherichia coli O157:H7 target Peyer's patches in humans and cause attaching/effacing lesions in both human and bovine intestine. Gut 2000 47 (3) 377-381
36. Chong Y, Fitzhenry R, Heuschkel R, Torrente F, Frankel G, Phillips A D. Human intestinal tissue tropism in Escherichia coli O157: H7initial colonization of terminal ileum and Peyer's patches and minimal colonic adhesion ex vivo. Microbiology 2007 153 (Pt 3) 794-802
37. Nataro J P., Kaper J B. Diarrheagenic Escherichia coli. Clin Microbiol Rev 1998 11 (1) 142-201
38. Pacheco A R., Sperandio V. Inter-kingdom signaling: chemical language between bacteria and host. Curr Opin Microbiol 2009 12 (2) 192-198
39. Hughes D T., Clarke M B., Yamamoto K, Rasko D A., Sperandio V. The QseC adrenergic signaling cascade in enterohemorrhagic E. coli (EHEC). PLoS Pathog 2009 5 (8) e1000553
40. Dytoc M T., Ismaili A, Philpott D J., Soni R, Brunton J L., Sherman P M. Distinct binding properties of eaeA-negative verocytotoxin-producing Escherichia coli of serotype O113:H21. Infect Immun 1994 62 (8) 3494-3505
41. Vidal M, Prado V, Whitlock G C., Solari A, Torres A G., Vidal R M. Subtractive hybridization and identification of putative adhesins in a Shiga toxin-producing eae-negative Escherichia coli. Microbiology 2008 154 (Pt 12) 3639-3648
42. Bardiau M, Labrozzo S, Mainil J G. Putative adhesins of enteropathogenic and enterohemorrhagic Escherichia coli of serogroup O26 isolated from humans and cattle. J Clin Microbiol 2009 47 (7) 2090-2096
43. Mundy R, Jenkins C, Yu J, Smith H, Frankel G. Distribution of espI among clinical enterohaemorrhagic and enteropathogenic Escherichia coli isolates. J Med Microbiol 2004 53 (Pt 11) 1145-1149
44. Xicohtencatl-Cortes J, Monteiro-Neto V, Saldaa Z, Ledesma M A., Puente J L., Girón J A. The type 4 pili of enterohemorrhagic Escherichia coli O157:H7 are multipurpose structures with pathogenic attributes. J Bacteriol 2009 191 (1) 411-421
45. Fontaine A, Arondel J, Sansonetti P J. Role of Shiga toxin in the pathogenesis of bacillary dysentery, studied by using a Tox- mutant of Shigella dysenteriae 1. Infect Immun 1988 56 (12) 3099-3109
46. Schüller S, Heuschkel R, Torrente F, Kaper J B., Phillips A D. Shiga toxin binding in normal and inflamed human intestinal mucosa. Microbes Infect 2007 9 (1) 35-39
47. Smith W E., Kane A V., Campbell S T., Acheson D W., Cochran B H., Thorpe C M. Shiga toxin 1 triggers a ribotoxic stress response leading to p38 and JNK activation and induction of apoptosis in intestinal epithelial cells. Infect Immun 2003 71 (3) 1497-1504
48. Schüller S, Frankel G, Phillips A D. Interaction of Shiga toxin from Escherichia coli with human intestinal epithelial cell lines and explants: Stx2 induces epithelial damage in organ culture. Cell Microbiol 2004 6 (3) 289-301
49. Kashiwamura M, Kurohane K, Tanikawa T, Deguchi A, Miyamoto D, Imai Y. Shiga toxin kills epithelial cells isolated from distal but not proximal part of mouse colon. Biol Pharm Bull 2009 32 (9) 1614-1617
50. Hurley B P., Jacewicz M, Thorpe C M. et al. Shiga toxins 1 and 2 translocate differently across polarized intestinal epithelial cells. Infect Immun 1999 67 (12) 6670-6677
51. Hurley B P., Thorpe C M., Acheson D W. Shiga toxin translocation across intestinal epithelial cells is enhanced by neutrophil transmigration. Infect Immun 2001 69 (10) 6148-6155
52. de Sablet T, Chassard C, Bernalier-Donadille A, Vareille M, Gobert A P., Martin C. Human microbiota-secreted factors inhibit shiga toxin synthesis by enterohemorrhagic Escherichia coli O157:H7. Infect Immun 2009 77 (2) 783-790
53. Bielaszewska M, Friedrich A W., Aldick T, Schürk-Bulgrin R, Karch H. Shiga toxin activatable by intestinal mucus in Escherichia coli isolated from humans: predictor for a severe clinical outcome. Clin Infect Dis 2006 43 (9) 1160-1167
54. Cherla R P., Lee S Y., Tesh V L. Shiga toxins and apoptosis. FEMS Microbiol Lett 2003 228 (2) 159-166
55. Byres E, Paton A W., Paton J C. et al. Incorporation of a non-human glycan mediates human susceptibility to a bacterial toxin. Nature 2008 456 (7222) 648-652
56. Löfling J C., Paton A W., Varki N M., Paton J C., Varki A. A dietary non-human sialic acid may facilitate hemolytic-uremic syndrome. Kidney Int 2009 76 (2) 140-144
57. Thorpe C M., Hurley B P., Lincicome L L., Jacewicz M S., Keusch G T., Acheson D W. Shiga toxins stimulate secretion of interleukin-8 from intestinal epithelial cells. Infect Immun 1999 67 (11) 5985-5993
58. Thorpe C M., Smith W E., Hurley B P., Acheson D W. Shiga toxins induce, superinduce, and stabilize a variety of C-X-C chemokine mRNAs in intestinal epithelial cells, resulting in increased chemokine expression. Infect Immun 2001 69 (10) 6140-6147
59. Bellmeyer A, Cotton C, Kanteti R, Koutsouris A, Viswanathan V K., Hecht G. Enterohemorrhagic Escherichia coli suppresses inflammatory response to cytokines and its own toxin. Am J Physiol Gastrointest Liver Physiol 2009 297 (3) G576-G581
60. van de Kar N C., Monnens L A., Karmali M A., van Hinsbergh V W. Tumor necrosis factor and interleukin-1 induce expression of the verocytotoxin receptor globotriaosylceramide on human endothelial cells: implications for the pathogenesis of the hemolytic uremic syndrome. Blood 1992 80 (11) 2755-2764
61. Karpman D, Connell H, Svensson M, Scheutz F, Alm P, Svanborg C. The role of lipopolysaccharide and Shiga-like toxin in a mouse model of Escherichia coli O157:H7 infection. J Infect Dis 1997 175 (3) 611-620
62. Calderon Toledo C, Rogers T J., Svensson M et al. Shiga toxin-mediated disease in MyD88-deficient mice infected with Escherichia coli O157:H7. Am J Pathol 2008 173 (5) 1428-1439
63. Iimura M, Gallo R L., Hase K, Miyamoto Y, Eckmann L, Kagnoff M F. Cathelicidin mediates innate intestinal defense against colonization with epithelial adherent bacterial pathogens. J Immunol 2005 174 (8) 4901-4907
64. Sthl A L., Sartz L, Nelsson A, Békássy Z D., Karpman D. Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome. PLoS One 2009 4 (9) e6990
65. Sthl A L., Svensson M, Mörgelin M et al. Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to platelets through TLR4 and CD62 and is detected on circulating platelets in patients with hemolytic uremic syndrome. Blood 2006 108 (1) 167-176
66. Tazzari P L., Ricci F, Carnicelli D et al. Flow cytometry detection of Shiga toxins in the blood from children with hemolytic uremic syndrome. Cytometry B Clin Cytom 2004 61 (1) 40-44
67. Cooling L L., Walker K E., Gille T, Koerner T A. Shiga toxin binds human platelets via globotriaosylceramide (Pk antigen) and a novel platelet glycosphingolipid. Infect Immun 1998 66 (9) 4355-4366
68. te Loo D M., Monnens L A., van Der Velden T J. et al. Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. Blood 2000 95 (11) 3396-3402
69. van Setten P A., Monnens L A., Verstraten R G., van den Heuvel L P., van Hinsbergh V W. Effects of verocytotoxin-1 on nonadherent human monocytes: binding characteristics, protein synthesis, and induction of cytokine release. Blood 1996 88 (1) 174-183
70. Obrig T G., Moran T P., Colinas R J. Ribonuclease activity associated with the 60S ribosome-inactivating proteins ricin A, phytolaccin and Shiga toxin. Biochem Biophys Res Commun 1985 130 (2) 879-884
71. Liu J, Akahoshi T, Sasahana T et al. Inhibition of neutrophil apoptosis by verotoxin 2 derived from Escherichia coli O157:H7. Infect Immun 1999 67 (11) 6203-6205
72. Cohen A, Madrid-Marina V, Estrov Z, Freedman M H., Lingwood C A., Dosch H M. Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: a mechanism for the failure of long-lived antibody response to dysenteric disease. Int Immunol 1990 2 (1) 1-8
73. Brigotti M, Carnicelli D, Ravanelli E et al. Interactions between Shiga toxins and human polymorphonuclear leukocytes. J Leukoc Biol 2008 84 (4) 1019-1027
74. Lee S Y., Cherla R P., Tesh V L. Simultaneous induction of apoptotic and survival signaling pathways in macrophage-like THP-1 cells by Shiga toxin 1. Infect Immun 2007 75 (3) 1291-1302
75. Walters M D., Matthei I U., Kay R, Dillon M J., Barratt T M. The polymorphonuclear leucocyte count in childhood haemolytic uraemic syndrome. Pediatr Nephrol 1989 3 (2) 130-134
76. Fitzpatrick M M., Shah V, Filler G, Dillon M J., Barratt T M. Neutrophil activation in the haemolytic uraemic syndrome: free and complexed elastase in plasma. Pediatr Nephrol 1992 6 (1) 50-53
77. Fernandez G C., Gomez S A., Ramos M V. et al. The functional state of neutrophils correlates with the severity of renal dysfunction in children with hemolytic uremic syndrome. Pediatr Res 2007 61 (1) 123-128
78. Fernandez G C., Lopez M F., Gomez S A. et al. Relevance of neutrophils in the murine model of haemolytic uraemic syndrome: mechanisms involved in Shiga toxin type 2-induced neutrophilia. Clin Exp Immunol 2006 146 (1) 76-84
79. Szabady R L., Lokuta M A., Walters K B., Huttenlocher A, Welch R A. Modulation of neutrophil function by a secreted mucinase of Escherichia coli O157:H7. PLoS Pathog 2009 5 (2) e1000320
80. Inward C D., Howie A J., Fitzpatrick M M., Rafaat F, Milford D V., Taylor C M., British Association for Paediatric Nephrology. Renal histopathology in fatal cases of diarrhoea-associated haemolytic uraemic syndrome. Pediatr Nephrol 1997 11 (5) 556-559
81. Exeni R A., Fernandez G C., Palermo M S. Role of polymorphonuclear leukocytes in the pathophysiology of typical hemolytic uremic syndrome. Scient World J 2007 7 1155-1164
82. Geelen J M., van der Velden T J., van den Heuvel L P., Monnens L A. Interactions of Shiga-like toxin with human peripheral blood monocytes. Pediatr Nephrol 2007 22 (8) 1181-1187
83. Sakiri R, Ramegowda B, Tesh V L. Shiga toxin type 1 activates tumor necrosis factor-alpha gene transcription and nuclear translocation of the transcriptional activators nuclear factor-kappaB and activator protein-1. Blood 1998 92 (2) 558-566
84. Guessous F, Marcinkiewicz M, Polanowska-Grabowska R, Keepers T R., Obrig T, Gear A R. Shiga toxin 2 and lipopolysaccharide cause monocytic THP-1 cells to release factors which activate platelet function. Thromb Haemost 2005 94 (5) 1019-1027
85. Murata K, Higuchi T, Takada K, Oida K, Horie S, Ishii H. Verotoxin-1 stimulation of macrophage-like THP-1 cells up-regulates tissue factor expression through activation of c-Yes tyrosine kinase: Possible signal transduction in tissue factor up-regulation. Biochim Biophys Acta 2006 1762 (9) 835-843
86. Karpman D, Manea M, Vaziri-Sani F, Sthl A L., Kristoffersson A C. Platelet activation in hemolytic uremic syndrome. Semin Thromb Hemost 2006 32 (2) 128-145
87. Karpman D, Papadopoulou D, Nilsson K, Sjögren A C., Mikaelsson C, Lethagen S. Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome. Blood 2001 97 (10) 3100-3108
88. Ghosh S A., Polanowska-Grabowska R K., Fujii J, Obrig T, Gear A R. Shiga toxin binds to activated platelets. J Thromb Haemost 2004 2 (3) 499-506
89. Keepers T R., Psotka M A., Gross L K., Obrig T G. A murine model of HUS: Shiga toxin with lipopolysaccharide mimics the renal damage and physiologic response of human disease. J Am Soc Nephrol 2006 17 (12) 3404-3414
90. Kamitsuji H, Nonami K, Murakami T, Ishikawa N, Nakayama A, Umeki Y. Elevated tissue factor circulating levels in children with hemolytic uremic syndrome caused by verotoxin-producing E. coli. Clin Nephrol 2000 53 (5) 319-324
91. Ishii H, Takada K, Higuchi T, Sugiyama J. Verotoxin-1 induces tissue factor expression in human umbilical vein endothelial cells through activation of NF-kappaB/Rel and AP-1. Thromb Haemost 2000 84 (4) 712-721
92. Nestoridi E, Tsukurov O, Kushak R I., Ingelfinger J R., Grabowski E F. Shiga toxin enhances functional tissue factor on human glomerular endothelial cells: implications for the pathophysiology of hemolytic uremic syndrome. J Thromb Haemost 2005 3 (4) 752-762
93. Nestoridi E, Kushak R I., Tsukurov O, Grabowski E F., Ingelfinger J R. Role of the renin angiotensin system in TNF-alpha and Shiga-toxin-induced tissue factor expression. Pediatr Nephrol 2008 23 (2) 221-231
94. Sugatani J, Igarashi T, Munakata M et al. Activation of coagulation in C57BL/6 mice given verotoxin 2 (VT2) and the effect of co-administration of LPS with VT2. Thromb Res 2000 100 (1) 61-72
95. Raife T, Friedman K D., Fenwick B. Lepirudin prevents lethal effects of Shiga toxin in a canine model. Thromb Haemost 2004 92 (2) 387-393
96. Taylor F B. Jr, Tesh V L., DeBault L et al. Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1. Am J Pathol 1999 154 (4) 1285-1299
97. Tri S, Németh I, Vargha I, Matkovics B. Oxidative damage of red blood cells in haemolytic uraemic syndrome. Pediatr Nephrol 1994 8 (1) 26-29
98. Bitzan M, Bickford B B., Foster G H. Verotoxin (shiga toxin) sensitizes renal epithelial cells to increased heme toxicity: possible implications for the hemolytic uremic syndrome. J Am Soc Nephrol 2004 15 (9) 2334-2343
99. Gallo E G., Gianantonio C A. Extrarenal involvement in diarrhoea-associated haemolytic-uraemic syndrome. Pediatr Nephrol 1995 9 (1) 117-119
100. Hughes A K., Ergonul Z, Stricklett P K., Kohan D E., Ergonal Z. Molecular basis for high renal cell sensitivity to the cytotoxic effects of shigatoxin-1: upregulation of globotriaosylceramide expression. J Am Soc Nephrol 2002 13 (9) 2239-2245
101. Okuda T, Tokuda N, Numata S et al. Targeted disruption of Gb3/CD77 synthase gene resulted in the complete deletion of globo-series glycosphingolipids and loss of sensitivity to verotoxins. J Biol Chem 2006 281 (15) 10230-10235
102. Ergonul Z, Clayton F, Fogo A B., Kohan D E. Shigatoxin-1 binding and receptor expression in human kidneys do not change with age. Pediatr Nephrol 2003 18 (3) 246-253
103. Karpman D, Hkansson A, Perez M T. et al. Apoptosis of renal cortical cells in the hemolytic-uremic syndrome: in vivo and in vitro studies. Infect Immun 1998 66 (2) 636-644
104. Kaneko K, Kiyokawa N, Ohtomo Y et al. Apoptosis of renal tubular cells in Shiga-toxin-mediated hemolytic uremic syndrome. Nephron 2001 87 (2) 182-185
105. van Setten P A., van Hinsbergh V W., van der Velden T J. et al. Effects of TNF alpha on verocytotoxin cytotoxicity in purified human glomerular microvascular endothelial cells. Kidney Int 1997 51 (4) 1245-1256
106. Pijpers A H., van Setten P A., van den Heuvel L P. et al. Verocytotoxin-induced apoptosis of human microvascular endothelial cells. J Am Soc Nephrol 2001 12 (4) 767-778
107. Williams J M., Boyd B, Nutikka A et al. A comparison of the effects of verocytotoxin-1 on primary human renal cell cultures. Toxicol Lett 1999 105 (1) 47-57
108. Hughes A K., Stricklett P K., Schmid D, Kohan D E. Cytotoxic effect of Shiga toxin-1 on human glomerular epithelial cells. Kidney Int 2000 57 (6) 2350-2359
109. Hughes A K., Stricklett P K., Kohan D E. Shiga toxin-1 regulation of cytokine production by human glomerular epithelial cells. Nephron 2001 88 (1) 14-23
110. Lee J E., Kim J S., Choi I H., Tagawa M, Kohsaka T, Jin D K. Cytokine expression in the renal tubular epithelial cells stimulated by Shiga toxin 2 of Escherichia coli O157:H7. Ren Fail 2002 24 (5) 567-575
111. Zanchi C, Zoja C, Morigi M et al. Fractalkine and CX3CR1 mediate leukocyte capture by endothelium in response to Shiga toxin. J Immunol 2008 181 (2) 1460-1469
112. Ramos M V., Fernández G C., Patey N et al. Involvement of the fractalkine pathway in the pathogenesis of childhood hemolytic uremic syndrome. Blood 2007 109 (6) 2438-2445
113. Trachtman H, Christen E, Cnaan A et al, Investigators of the HUS-SYNSORB Pk Multicenter Clinical Trial. Urinary neutrophil gelatinase-associated lipocalcin in D+ HUS: a novel marker of renal injury. Pediatr Nephrol 2006 21 (7) 989-994
114. Ake J A., Jelacic S, Ciol M A. et al. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Pediatrics 2005 115 (6) e673-e680
115. Wadolkowski E A., Sung L M., Burris J A., Samuel J E., O'Brien A D. Acute renal tubular necrosis and death of mice orally infected with Escherichia coli strains that produce Shiga-like toxin type II. Infect Immun 1990 58 (12) 3959-3965
116. Zotta E, Lago N, Ochoa F, Repetto H A., Ibarra C. Development of an experimental hemolytic uremic syndrome in rats. Pediatr Nephrol 2008 23 (4) 559-567
117. Silberstein C, Pistone Creydt V, Gerhardt E, Nez P, Ibarra C. Inhibition of water absorption in human proximal tubular epithelial cells in response to Shiga toxin-2. Pediatr Nephrol 2008 23 (11) 1981-1990
118. Sugatani J, Komiyama N, Mochizuki T et al. Urinary concentrating defect in rats given Shiga toxin: elevation in urinary AQP2 level associated with polyuria. Life Sci 2002 71 (2) 171-189
119. Psotka M A., Obata F, Kolling G L. et al. Shiga toxin 2 targets the murine renal collecting duct epithelium. Infect Immun 2009 77 (3) 959-969
120. Nestoridi E, Kushak R I., Duguerre D, Grabowski E F., Ingelfinger J R. Up-regulation of tissue factor activity on human proximal tubular epithelial cells in response to Shiga toxin. Kidney Int 2005 67 (6) 2254-2266
121. Morigi M, Buelli S, Zanchi C et al. Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling. Am J Pathol 2006 169 (6) 1965-1975
122. Bitzan M M., Wang Y, Lin J, Marsden P A. Verotoxin and ricin have novel effects on preproendothelin-1 expression but fail to modify nitric oxide synthase (ecNOS) expression and NO production in vascular endothelium. J Clin Invest 1998 101 (2) 372-382
123. Shigematsu H, Dikman S H., Churg J, Grishman E, Duffy J L. Mesangial involvement in hemolytic-uremic syndrome. A light and electron microscopic study. Am J Pathol 1976 85 (2) 349-362
124. Warnier M, Römer W, Geelen J et al. Trafficking of Shiga toxin/Shiga-like toxin-1 in human glomerular microvascular endothelial cells and human mesangial cells. Kidney Int 2006 70 (12) 2085-2091
125. Simon M, Cleary T G., Hernandez J D., Abboud H E. Shiga toxin 1 elicits diverse biologic responses in mesangial cells. Kidney Int 1998 54 (4) 1117-1127
126. Te Loo D M., Monnens L, van der Velden T, Karmali M, van den Heuvel L, van Hinsbergh V. Shiga toxin-1 affects nitric oxide production by human glomerular endothelial and mesangial cells. Pediatr Nephrol 2006 21 (12) 1815-1823
127. Van Setten P A., van Hinsbergh V W., Van den Heuvel L P. et al. Verocytotoxin inhibits mitogenesis and protein synthesis in purified human glomerular mesangial cells without affecting cell viability: evidence for two distinct mechanisms. J Am Soc Nephrol 1997 8 (12) 1877-1888
128. Obata F, Tohyama K, Bonev A D. et al. Shiga toxin 2 affects the central nervous system through receptor globotriaosylceramide localized to neurons. J Infect Dis 2008 198 (9) 1398-1406
129. Fujii J, Wood K, Matsuda F et al. Shiga toxin 2 causes apoptosis in human brain microvascular endothelial cells via C/EBP homologous protein. Infect Immun 2008 76 (8) 3679-3689
130. Ergonul Z, Hughes A K., Kohan D E. Induction of apoptosis of human brain microvascular endothelial cells by Shiga toxin 1. J Infect Dis 2003 187 (1) 154-158
131. Stricklett P K., Hughes A K., Ergonul Z, Kohan D E. Molecular basis for up-regulation by inflammatory cytokines of Shiga toxin 1 cytotoxicity and globotriaosylceramide expression. J Infect Dis 2002 186 (7) 976-982
132. Goldstein J, Loidl C F., Creydt V P., Boccoli J, Ibarra C. Intracerebroventricular administration of Shiga toxin type 2 induces striatal neuronal death and glial alterations: an ultrastructural study. Brain Res 2007 1161 106-115
133. Boccoli J, Loidl C F., Lopez-Costa J J., Creydt V P., Ibarra C, Goldstein J. Intracerebroventricular administration of Shiga toxin type 2 altered the expression levels of neuronal nitric oxide synthase and glial fibrillary acidic protein in rat brains. Brain Res 2008 1230 320-333
134. Eisenhauer P B., Jacewicz M S., Conn K J. et al. Escherichia coli Shiga toxin 1 and TNF-alpha induce cytokine release by human cerebral microvascular endothelial cells. Microb Pathog 2004 36 (4) 189-196
135. Manuelian T, Hellwage J, Meri S et al. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest 2003 111 (8) 1181-1190
136. Sthl A L., Vaziri-Sani F, Heinen S et al. Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood 2008 111 (11) 5307-5315
137. Thurman J M., Marians R, Emlen W et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009 4 (12) 1920-1924
138. Orth D, Khan A B., Naim A et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 2009 182 (10) 6394-6400
139. Hughes D T., Sperandio V. Inter-kingdom signalling: communication between bacteria and their hosts. Nat Rev Microbiol 2008 6 (2) 111-120
140. Chandler W L., Jelacic S, Boster D R. et al. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med 2002 346 (1) 23-32
141. Manea M, Kristoffersson A, Schneppenheim R et al. Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura. Br J Haematol 2007 138 (5) 651-662 (Pubitemid 47206716)